Novo Nordisk logoNovo NordiskView brand email archive

Novo Nordisk A/S: Denecimig (Mim8) significantly reduced annualised bleeding rate in people with haemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

Novo Nordisk A/S: Denecimig (Mim8) significantly reduced annualised bleeding rate in people with haemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM email from Novo Nordisk screenshot
Screenshot preview · Scroll to view the full email

Archived for design inspiration. Original email and brand assets belong to their respective owners. Design observations describe the creative; they are not campaign results.